Abstract
Objective: Results of direct comparative studies between ezetimibe/simvastatin and rosuvastatin therapies have not been reported. Both of these treatment options offer significant reductions in LDL-C. To evaluate the lipid efficacy of each of these therapies relative to each other, a metaanalysis of data from 14 randomized, double-blind clinical trials that compared the effectiveness of two new options for cholesterol lowering was performed. Data sources: PubMed, EMBASE and BIOSIS databases were searched up to March 14,2004. Methods of study selection: Efficacy results from clinical trials with the co-administration of ezetimibe 10mg with simvastatin or with the ezetimibe/simvastatin combination product (ezetimibe/simvastatin 10/10 mg, 10/20mg, 10/40mg, and 10/80mg) were compared with efficacy results from clinical trials of rosuvastatin 5mg, 10mg, 20 mg, and 40 mg in patients with primary hypercholesterolemia. Trials in healthy patients, heterozygous familial hypercholesterolemia or combined hyperlipidemia, and pharmacokinetic trials were excluded. Data extraction and synthesis: This analysis used pooled data for LDL-C, HDL-C, non-HDL-C, triglycerides, total cholesterol, apolipoprotein (apo) A-I, and apo B for the two therapies at their lowest doses (ezetimibe/ simvastatin 10/10 mg and rosuvastatin 5mg) through their highest doses (ezetimibe/simvastatin 10/80mg and rosuvastatin 40 mg), and estimated within-treatment percentage changes in these parameters. Percentage reductions from baseline in LDL-C for the pooled data were 46.2% and 41.8% for ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg, respectively; 50.6% and 47.4% for ezetimibe/simvastatin 10/20mg and rosuvastatin 10mg, respectively; 55.9% and 52.1% for ezetimibe/simvastatin 10/40mg and rosuvastatin 20 mg, respectively; and 59.7% and 58.5% for ezetimibe/simvastatin 10/80mg and rosuvastatin 40 mg, respectively. Conclusions: The results of this meta-analysis suggest greater LDL-C lowering with ezetimibe/ simvastatin compared with rosuvastatin. These results need to be confirmed in a head-to-head comparison of both therapies.
| Original language | English |
|---|---|
| Pages (from-to) | 1123-1130 |
| Number of pages | 8 |
| Journal | Current Medical Research and Opinion |
| Volume | 21 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2005 |
Fingerprint
Keywords
- Ezetimibe
- Hypercholesterolemia
- Lipids
- Meta-analysis
- Statin therapies
ASJC Scopus subject areas
- Medicine(all)
Cite this
Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin : A meta-analysis of pooled data from 14 clinical trials. / Catapano, Alberico; Brady, William E.; King, Thomas R.; Palmisano, Joanne.
In: Current Medical Research and Opinion, Vol. 21, No. 7, 07.2005, p. 1123-1130.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin
T2 - A meta-analysis of pooled data from 14 clinical trials
AU - Catapano, Alberico
AU - Brady, William E.
AU - King, Thomas R.
AU - Palmisano, Joanne
PY - 2005/7
Y1 - 2005/7
N2 - Objective: Results of direct comparative studies between ezetimibe/simvastatin and rosuvastatin therapies have not been reported. Both of these treatment options offer significant reductions in LDL-C. To evaluate the lipid efficacy of each of these therapies relative to each other, a metaanalysis of data from 14 randomized, double-blind clinical trials that compared the effectiveness of two new options for cholesterol lowering was performed. Data sources: PubMed, EMBASE and BIOSIS databases were searched up to March 14,2004. Methods of study selection: Efficacy results from clinical trials with the co-administration of ezetimibe 10mg with simvastatin or with the ezetimibe/simvastatin combination product (ezetimibe/simvastatin 10/10 mg, 10/20mg, 10/40mg, and 10/80mg) were compared with efficacy results from clinical trials of rosuvastatin 5mg, 10mg, 20 mg, and 40 mg in patients with primary hypercholesterolemia. Trials in healthy patients, heterozygous familial hypercholesterolemia or combined hyperlipidemia, and pharmacokinetic trials were excluded. Data extraction and synthesis: This analysis used pooled data for LDL-C, HDL-C, non-HDL-C, triglycerides, total cholesterol, apolipoprotein (apo) A-I, and apo B for the two therapies at their lowest doses (ezetimibe/ simvastatin 10/10 mg and rosuvastatin 5mg) through their highest doses (ezetimibe/simvastatin 10/80mg and rosuvastatin 40 mg), and estimated within-treatment percentage changes in these parameters. Percentage reductions from baseline in LDL-C for the pooled data were 46.2% and 41.8% for ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg, respectively; 50.6% and 47.4% for ezetimibe/simvastatin 10/20mg and rosuvastatin 10mg, respectively; 55.9% and 52.1% for ezetimibe/simvastatin 10/40mg and rosuvastatin 20 mg, respectively; and 59.7% and 58.5% for ezetimibe/simvastatin 10/80mg and rosuvastatin 40 mg, respectively. Conclusions: The results of this meta-analysis suggest greater LDL-C lowering with ezetimibe/ simvastatin compared with rosuvastatin. These results need to be confirmed in a head-to-head comparison of both therapies.
AB - Objective: Results of direct comparative studies between ezetimibe/simvastatin and rosuvastatin therapies have not been reported. Both of these treatment options offer significant reductions in LDL-C. To evaluate the lipid efficacy of each of these therapies relative to each other, a metaanalysis of data from 14 randomized, double-blind clinical trials that compared the effectiveness of two new options for cholesterol lowering was performed. Data sources: PubMed, EMBASE and BIOSIS databases were searched up to March 14,2004. Methods of study selection: Efficacy results from clinical trials with the co-administration of ezetimibe 10mg with simvastatin or with the ezetimibe/simvastatin combination product (ezetimibe/simvastatin 10/10 mg, 10/20mg, 10/40mg, and 10/80mg) were compared with efficacy results from clinical trials of rosuvastatin 5mg, 10mg, 20 mg, and 40 mg in patients with primary hypercholesterolemia. Trials in healthy patients, heterozygous familial hypercholesterolemia or combined hyperlipidemia, and pharmacokinetic trials were excluded. Data extraction and synthesis: This analysis used pooled data for LDL-C, HDL-C, non-HDL-C, triglycerides, total cholesterol, apolipoprotein (apo) A-I, and apo B for the two therapies at their lowest doses (ezetimibe/ simvastatin 10/10 mg and rosuvastatin 5mg) through their highest doses (ezetimibe/simvastatin 10/80mg and rosuvastatin 40 mg), and estimated within-treatment percentage changes in these parameters. Percentage reductions from baseline in LDL-C for the pooled data were 46.2% and 41.8% for ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg, respectively; 50.6% and 47.4% for ezetimibe/simvastatin 10/20mg and rosuvastatin 10mg, respectively; 55.9% and 52.1% for ezetimibe/simvastatin 10/40mg and rosuvastatin 20 mg, respectively; and 59.7% and 58.5% for ezetimibe/simvastatin 10/80mg and rosuvastatin 40 mg, respectively. Conclusions: The results of this meta-analysis suggest greater LDL-C lowering with ezetimibe/ simvastatin compared with rosuvastatin. These results need to be confirmed in a head-to-head comparison of both therapies.
KW - Ezetimibe
KW - Hypercholesterolemia
KW - Lipids
KW - Meta-analysis
KW - Statin therapies
UR - http://www.scopus.com/inward/record.url?scp=22744436166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22744436166&partnerID=8YFLogxK
U2 - 10.1185/030079905X50642
DO - 10.1185/030079905X50642
M3 - Article
C2 - 16004682
AN - SCOPUS:22744436166
VL - 21
SP - 1123
EP - 1130
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
SN - 0300-7995
IS - 7
ER -